Oral absorption and pharmacokinetics of rebamipide and rebamipide lysinate in rats

Drug Development and Industrial Pharmacy

Volumn 30, Issue 8, 2004, Pages 869-876

  Beom, Soo Shin ^a   Chul, Hwan Kim ^a   Yoon, Sik Jun ^a   Chi, Ho Yoon ^a   Jae, Il Rho ^b   Lee, Kang Choon ^a   Hye, Seon Han ^a   Sun, Dong Yoo ^a  

^a Sungkyunkwan University   (South Korea)

^b II Yang Pharm Co Ltd   (South Korea)

Author keywords

Absorption; Bioavailability; Pharmacokinetics; Rebamipide; Rebamipide lysinate

Indexed keywords

ANTIULCER AGENT; DIMETHYL SULFOXIDE; MACROGOL; OPC 1759; REBAMIPIDE; REBAMIPIDE LYSINATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG SOLUBILITY; INTESTINE FLUID; MALE; NONHUMAN; PH; RAT; STATISTICAL SIGNIFICANCE; STOMACH JUICE;

ADMINISTRATION, ORAL; ALANINE; ANIMALS; ANTI-ULCER AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DRUG EVALUATION, PRECLINICAL; HALF-LIFE; HYDROGEN-ION CONCENTRATION; INJECTIONS, INTRAVENOUS; MALE; QUINOLONES; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; WATER;

EID: 5444250003     PISSN: 03639045     EISSN: None     Source Type: Journal    
DOI: 10.1081/DDC-200034577     Document Type: Article

References (21)

1. Yamasaki, K.; Kanbe, T.; Chijiwa, T.; Ishiyama, H.; Morita, S. Gastric mucosal protection by OPC-12759, a novel antiulcer compound, in the rat. Eur. J. Pharmacol. 1987, 142, 23-30.
2. Yamasaki, K.; Ishihara, H.; Imaizumi, T.; Kabe, T.; Yabuuchi, Y. Effect of OPC-12759, a novel antiulcer agent, on chronic and acute experimental gastric ulcer and gastric secretion in rats. Jpn. J. Pharmacol. 1989, 49, 441-448.
3. Arakawa, T.; Kobayashi, K.; Yoshikawa, T.; Tarnawski, A. Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing. Dig. Dis. Sci. 1998, 43, 5S-13S.
4. Ishihara, K.; Komuro, Y.; Nishiyama, N.; Yamasaki, K.; Hotta, K. Effect of rebamipide on mucus secretion by endogenous prostaglandin-independent mechanism in rat gastric mucosa. Arzneim. -Forsch./Drug Res. 1992, 42, 1462-1466.
5. Mizoguchi, H.; Ogawa, Y.; Kanatsu, K.; Tanaka, A.; Kato, S.; Takeuchi, K. Protective effect of rebamipide on indomethacin-induced intestinal damage in rats. J. Gastroenterol. Hepatol. 2001, 16, 1112-1119.
6. Udagawa, A.; Shiota, G.; Ichiba, M.; Murakawa, Y. Effect of rebamipide on acetic acid-induced gastric ulcer in rats: involvement of hepatic growth factor. Scand. J. Gastroenterol. 2003, 38, 141-146.
7. Kishimoto, S.; Haruma, K.; Tari, A.; Sakurai, K.; Nakano, M.; Nakagawa, Y. Rebamipide, an anti-ulcer drug, prevents DSS-induced colitis formation in rats. Dig. Dis. Sci. 2000, 45, 1608-1616.
8. Miyake, M.; Oka, Y.; Minami, T.; Toguchi, H.; Odomi, M.; Ogawara, K.; Higaki, K.; Kimura, T. Combinatorial use of sodium laurate with taurine or L-glutamine enhances colonic absorption of rebamipide, poorly absorbable antiulcer drug, without any serious histopathological mucosal damages. J. Pharm.-Sci. 2003, 92, 911-921.
9. Shioya, Y.; Kashiyama, E.; Okada, K.; Kusumoto, N.; Abe, Y.; Uchida, M.; Shimizu, T. Metabolic fate of the anti-ulcer agent, (±)-2-(4- chlorobenzoylamino)-3-[2(1 H)quinolinon-4-yl]propionic acid (OPC-1759): absorption, distribution, and excretion in rats and dogs. Iyakuhin Kkenkyu 1989, 20, 522-533.
10. Fix, J.A. Absorption enhancing agents for the GI system. J. Control. Release 1987, 6, 151-156.
11. Lindmark, T.; Kimura, Y.; Artursson, P. Absorption enhancement through intracellular regulation of tight junction permeability by medium chain fatty acids in Caco-2 cells. J. Pharmacol. Exp. Ther. 1998, 284, 362-369.
12. Morris, K.R.; Fakes, M.G.; Thakur, A.B.; Singh, A.W.; Venit, J.J. An integrated approach to the selection of optimal salt form for a new drug candidate. Int. J. Pharm. 1994, 105, 209-217.
13. Engel, G.L.; Farid, N.A.; Faul, M.M.; Richardson, L.A.; Winneroski, L.L. Salt form selection and characterization of LY333531 mesylate monohydrate. Int. J. Pharm. 2000, 198, 239-247.
14. O'Connor, K.M.; Corrigan, O.I. Comparison of the physicochemical properties of the N-(2-hydroxyethyl) pyrrolidine, diethylamine and sodium salt forms of diclofenac. Int. J. Pharm. 2001, 222, 281-293.
15. Rho, J.I. A New Rebamipide Lysinate, Rebamipide Argininate and Pharmaceutical Preparation Containing the Same as Active Substance. Korea Patent 10 2003 0035382, June 2, 2003.
16. Naito, Y.; Yoshikawa, T.; Iinuma, S.; Miyazaki, R.; Yagi, N.; Yoshida, N.; Osumi, T.; Hirao, Y.; Kondo, M. Local gastric and serum concentrations of rebamipide following oral administration to patients with chronic gastritis. Arzneim.-Forsch./ Drug Res. 1996, 46, 698-700.
17. Shioya, Y.; Shimizu, T. High-performance liquid chromatographic procedure for the determination of a new anti-gastric agent, 2-(4-chlorobenzoyl-amino)-3- [2(1 H)quinolinon-4-yl]propionic acid, in human plasma and urine. J. Chromatogr. 1988, 434, 283-287.
18. Zhao, R.; Duan, J.; Yan, B. Determination of rebamipide in plasma by HPLC and its pharmacokinetic study. Zhongguo Yaoxue Zaxhi (Beizing) 1999, 34, 396-399.
19. Jamuludin, A.; Mohamad, M.; Navartnam, V.; Selliah, K.; Tan, S.C. Relative bioavailability of the hydrochloride, sulfate, and ethyl carbonate salts of quinine. Br. J. Clin. Pharmacol. 1988, 25, 262-263.
20. Walmsley, L.M.; Taylor, T.; Wilkinson, P.A.; Brodie, R.R.; Chasseaud, L.F.; Alun-Jones, V. Plasma concentrations and relative bioavailability of naftidrofuryl from different salt forms. Biopharm. Drug Dispos. 1986, 7, 327-334.
21. Akamatsu, T.; Nakamura, N.; Furuya, N.; Shimizu, T.; Gotou, A.; Kiyosawa, K.; Katsuyama, T.; Osumi, T.; Hirao, Y.; Miyamoto, G. Local gastric and serum concentrations of rebamipide following oral ingestion in healthy volunteers. Dig. Dis. Sci. 2002, 47, 1399-1404.